OpenAlex
PricingAboutJobs
Log inGet started
Work

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

HTML

Year: 2012
Type: article
Study design: Clinical Trial
Source: Blood
DOI: 10.1182/blood-2012-06-437558
Authors: Norbert Vey, Jean-Henri Bourhis, Nicolas Boissel, Dominique Bordessoule, Thomas Prebet, Aude Charbonnier, Anne Etienne, Pascale Andre, François Romagne, Don Benson, Herve Dombret, Daniel Olive
Institutions: Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Institut Gustave Roussy, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Limoges, Innate Pharma (France), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
Language: English

Topic: Immune Cell Function and Interaction
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W1985322758
FWCI: 11.55
Cites: 23
Cited by: 289
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms